Effects of modifying agents on conformity of enzyme phenotype and proliferative potential in focal preneoplastic and neoplastic liver cell lesions in rats. 1992

H Tsuda, and K Ozaki, and S Uwagawa, and S Yamaguchi, and K Hakoi, and T Aoki, and T Kato, and K Sato, and N Ito
First Department of Pathology, Nagoya City University Medical School.

Development of preneoplastic lesions in the rat liver under the influence of various modifiers was investigated with particular attention to changes in simultaneous expression of altered enzyme phenotype within the lesions (conformity) and proliferation potential. Degree of conformity of marker enzymes such as glutathione S-transferase placental form (GST-P), glucose-6-phosphate dehydrogenase (G6PD), glucose-6-phosphatase, adenosine triphosphatase and gamma-glutamyltranspeptidase was compared with levels of 5-bromo-2-deoxyuridine labeling. After initiation with diethylnitrosamine, rats were administered the hepatopromoter sodium phenobarbital (PB, 0.05%), the antioxidant ethoxyquin (EQ, 0.5%), or a peroxisome proliferator, clofibrate (CF, 1.0%) or di(2-ethylhexyl)-phthalate (0.3%) and killed at week 16 or 32. The PB promoting regimen was clearly associated with increase in the numbers of high conformity class lesions simultaneously expressing three to five enzymes, and elevated proliferation potential. The inhibitor, EQ, in contrast, brought about a time-dependent decrease in conformity so that only 1 or 2 alterations were most commonly observed at week 32. Lesion populations in the peroxisome proliferator- and especially CF-treated cases were characterized by obvious dissociation between degree of conformity and proliferative status. Such treatment-dependent differences were not always correlated with the size of the lesion. The results thus suggested that the conformity and proliferation potential of preneoplastic lesions are dependent on modification treatment. Overall, GST-P was found to be the most reliable marker, although G6PD was less influenced in the peroxisome proliferator cases.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D008297 Male Males
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D001973 Bromodeoxyuridine A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors. BUdR,BrdU,Bromouracil Deoxyriboside,Broxuridine,5-Bromo-2'-deoxyuridine,5-Bromodeoxyuridine,NSC-38297,5 Bromo 2' deoxyuridine,5 Bromodeoxyuridine,Deoxyriboside, Bromouracil
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002994 Clofibrate A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) Athromidin,Atromid,Atromid S,Clofibric Acid, Ethyl Ester,Ethyl Chlorophenoxyisobutyrate,Miscleron,Miskleron,Chlorophenoxyisobutyrate, Ethyl

Related Publications

H Tsuda, and K Ozaki, and S Uwagawa, and S Yamaguchi, and K Hakoi, and T Aoki, and T Kato, and K Sato, and N Ito
October 1990, Carcinogenesis,
H Tsuda, and K Ozaki, and S Uwagawa, and S Yamaguchi, and K Hakoi, and T Aoki, and T Kato, and K Sato, and N Ito
January 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology,
H Tsuda, and K Ozaki, and S Uwagawa, and S Yamaguchi, and K Hakoi, and T Aoki, and T Kato, and K Sato, and N Ito
July 2005, Histology and histopathology,
H Tsuda, and K Ozaki, and S Uwagawa, and S Yamaguchi, and K Hakoi, and T Aoki, and T Kato, and K Sato, and N Ito
March 1982, Cancer research,
H Tsuda, and K Ozaki, and S Uwagawa, and S Yamaguchi, and K Hakoi, and T Aoki, and T Kato, and K Sato, and N Ito
January 1993, Teratogenesis, carcinogenesis, and mutagenesis,
H Tsuda, and K Ozaki, and S Uwagawa, and S Yamaguchi, and K Hakoi, and T Aoki, and T Kato, and K Sato, and N Ito
December 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
H Tsuda, and K Ozaki, and S Uwagawa, and S Yamaguchi, and K Hakoi, and T Aoki, and T Kato, and K Sato, and N Ito
January 1992, Virchows Archiv. B, Cell pathology including molecular pathology,
H Tsuda, and K Ozaki, and S Uwagawa, and S Yamaguchi, and K Hakoi, and T Aoki, and T Kato, and K Sato, and N Ito
August 1998, Molecular carcinogenesis,
H Tsuda, and K Ozaki, and S Uwagawa, and S Yamaguchi, and K Hakoi, and T Aoki, and T Kato, and K Sato, and N Ito
January 1991, Progress in histochemistry and cytochemistry,
H Tsuda, and K Ozaki, and S Uwagawa, and S Yamaguchi, and K Hakoi, and T Aoki, and T Kato, and K Sato, and N Ito
January 1982, IARC scientific publications,
Copied contents to your clipboard!